Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
February 3, 2020: Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
January 30, 2020: Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering
January 29, 2020: Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team